http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 06:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html si-local-file:///var/storage/secattach/20260617/26656542.html http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html Wed, 17 Jun 2026 06:32:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html si-local-file:///var/storage/secattach/20260617/26656542.html http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html Wed, 17 Jun 2026 06:32:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html si-local-file:///var/storage/secattach/20260617/26656542.html http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html Wed, 17 Jun 2026 06:32:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html si-local-file:///var/storage/secattach/20260617/26656542.html http://www.streetinsider.com/SEC+Filings/Form++IRANNOTICE++TAKEDA+PHARMACEUTICAL++++++++++++++++/26656542.html Wed, 17 Jun 2026 06:32:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82">http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82</a></p> <p> Filed on: June 17, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html Wed, 17 Jun 2026 06:06:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82">http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82</a></p> <p> Filed on: June 17, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html Wed, 17 Jun 2026 06:06:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82">http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82</a></p> <p> Filed on: June 17, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html Wed, 17 Jun 2026 06:06:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82">http://archive.fast-edgar.com/20260617/AALZ922CZ22QV2Z2222B2CZG2DSSZZ225C82</a></p> <p> Filed on: June 17, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++TAKEDA+PHARMACEUTICAL+++++For%3A+Mar+31/26656467.html Wed, 17 Jun 2026 06:06:00 -0400 4502 O.00442316 O.05065998 TAK http://www.streetinsider.com/Intl+Ratings/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,500.00 (from JPY6,700.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Tue, 16 Jun 2026 07:12:29 -0400 TAK http://www.streetinsider.com/Intl+Ratings/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,500.00 (from JPY6,700.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Tue, 16 Jun 2026 07:12:29 -0400 TAK http://www.streetinsider.com/Analyst+PT+Change/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,500.00 (from JPY6,700.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Tue, 16 Jun 2026 07:12:29 -0400 TAK http://www.streetinsider.com/Analyst+PT+Change/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Nomura/Instinet analyst Hiroyuki Matsubara lowered the price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK) to JPY6,500.00 (from JPY6,700.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29+PT+Lowered+to+JPY6%2C500+at+NomuraInstinet/26650361.html Tue, 16 Jun 2026 07:12:29 -0400 TAK http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Neutral+Rating+on+Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29/26649349.html <p>Goldman Sachs analyst Akinori Ueda reiterated a Neutral rating and JPY5,300.00 price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK).</p> http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Neutral+Rating+on+Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29/26649349.html Tue, 16 Jun 2026 00:22:01 -0400 TAK http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Neutral+Rating+on+Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29/26649349.html <p>Goldman Sachs analyst Akinori Ueda reiterated a Neutral rating and JPY5,300.00 price target on Takeda Pharmaceutical (4502:JP) (NYSE: TAK).</p> http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Neutral+Rating+on+Takeda+Pharmaceutical+%284502%3AJP%29+%28TAK%29/26649349.html Tue, 16 Jun 2026 00:22:01 -0400 TAK http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Press+Releases/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html <p> - <i>Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms <br></br></i>- <i>Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review</i> </p> <p> OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&amp;esheet=54552126&amp;newsitemid=20260615651327&amp;lan=en-US&amp;anchor=TSE%3A4502%2FNYSE%3ATAK&amp;index=1&amp;md5=2735913f416631dcf87557e4849f8403" shape="rect">TSE:4502/NYSE:TAK</a>)<b> </b>today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 http://www.streetinsider.com/Business+Wire/New+Pivotal+Study+Data+Show+Takeda%E2%80%99s+Oveporexton+Improved+Daily+Function%2C+Cognition+and+Nighttime+Sleep+for+People+with+Narcolepsy+Type+1/26646093.html Mon, 15 Jun 2026 12:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK